Adaptive Biotechnologies Q1 revenue $70.9M, up 35% YoY; MRD revenue up 53%; raises FY2026 MRD guidance to $260-270M

Adaptive Biotechnologies Corp

2026-Q1 EPS reported -$0.13 revenue$70,874,000

Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).
Net loss narrowed to $20.0M from $29.8M; adj. EBITDA loss $2.5M improved from $12.7M loss.
Raised FY2026 MRD revenue guidance to $260-270M (from $255-265M), implying 22-27% annual growth.
Recognized $9.0M in MRD pharma regulatory milestone revenue, first U.S. primary endpoint milestone.
Immune Medicine revenue $3.8M (-57% YoY); cash & equivalents $237.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adaptive Biotechnologies Corp updated its full year 2026 guidance (raised).

Period: full year 2026
Guidance: raised
Result: guidance update

Exact text from the filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adaptive Biotechnologies Corp reported the quarter ended March 31, 2026 results: revenue $70.9 million, net income $20.0 million.

Period: the quarter ended March 31, 2026
Revenue: $70.9 million
Net income: $20.0 million
Result: reported results

Exact text from the filing

First Quarter 2026 Financial Results Revenue was $70.9 million for the quarter ended March 31, 2026, representing a 35% increase from the first quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended March 31, 2026, revenue for the current quarter increased 45% from the first quarter in the prior year. MRD revenue was $67.1 million for the quarter, representing a 53% increase from the first quarter in the prior year. Immune Medicine revenue was $3.8 million for the quarter, representing a 57% decrease from the first quarter in the prior year. Excluding revenue from the Genentech Agreement, Immune Medicine revenue for the quarter ended March 31, 2026 decreased 26% from the first quarter in the prior year. Operating expenses for the first quarter of 2026 were $90.1 million, compared to $82.0 million in the first quarter of the prior year, representing an increase of 10%. Interest and other income, net was

View on SEC.gov

Browse all earnings releases →

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0001193125-26-206455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.